Can glypican‐3 be a disease‐specific biomarker?

Chen, Chaolei; Huang, Xiaomin; Ying, Zhaojian; Wu, Dengmin; Yu, Yani; Wang, Xiangdong; Chen, Chengshui

doi:10.1186/s40169-017-0146-5

Cited by 21 publications

(21 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GPC3 is not only expressed on the surface of tumor cells, but also released into peripheral in soluble form (sGPC3). In combination with AFP, we can further improve the sensitivity in non-invasive diagnosis of liver tumors [5,33,70,75,76].…”

Section: Expression Of Gpc3 In Liver Cancer Tissuesmentioning

confidence: 99%

Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma

et al. 2020

View full text Add to dashboard Cite

Liver cancer is the second leading cause of cancer-related deaths worldwide, and hepatocellular carcinoma is the most common type. The pathogenesis of hepatocellular carcinoma is concealed, its progress is rapid, its prognosis is poor, and the mortality rate is high. Therefore, novel molecular targets for hepatocellular carcinoma early diagnosis and development of targeted therapy are critically needed. Glypican-3, a cell-surface glycoproteins in which heparan sulfate glycosaminoglycan chains are covalently linked to a protein core, is overexpressed in HCC tissues but not in the healthy adult liver. Thus, Glypican-3 is becoming a promising candidate for liver cancer diagnosis and immunotherapy. Up to now, Glypican-3 has been a reliable immunohistochemical marker for hepatocellular carcinoma diagnosis, and soluble Glypican-3 in serum has becoming a promising marker for liquid biopsy. Moreover, various immunotherapies targeting Glypican-3 have been developed, including Glypican-3 vaccines, anti-Glypican-3 immunotoxin and chimeric-antigen-receptor modified cells. In this review, we summarize and analyze the structure and physicochemical properties of Glypican-3 molecules, then review their biological functions and applications in clinical diagnosis, and explore the diagnosis and treatment strategies based on Glypican-3.

show abstract

Section: Expression Of Gpc3 In Liver Cancer Tissuesmentioning

confidence: 99%

Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Some studies show association between GPC3 gene and some types of liver cancer such as hepatocellular carcinoma. [30,34,71,72] Therefore, this study can open the door for novel diagnostic biomarkers for hepatocellular carcinoma. Combination detection of serum GPC3 and pathogenic SNPs through clinical and genetic testing must be positively matched; this can enhance accuracy and efficiency of hepatocellular carcinoma diagnosis.…”

Section: Discussionmentioning

confidence: 91%

Identification of Novel Key Biomarkers in Simpson-Golabi-Behmel Syndrome (SGBS): Evidence from Bioinformatics Analysis

Mustafa¹,

Abdelmoneim²,

Elfadol³

et al. 2019

Int. Ann. Sci.

View full text Add to dashboard Cite

The Simpson-Golabi-Behmel Syndrome (SGBS) or overgrowth Syndrome is an uncommon genetic X-linked disorder highlighted by macrosomia, renal defects, cardiac weaknesses and skeletal abnormalities. The purpose of the work was to classify the functional nsSNPs of GPC3 to serve as genetic biomarkers for overgrowth syndrome. The raw data of GPC3 gene were retrieved from dbSNP database and used to examine the most damaging effect using eight functional analysis tools, while we used I-mutant and MUPro to examine the effect of SNPs on GPC3 protein structure; The 3D structure of GPC3 protein is not found in the PDB, so RaptorX was used to create a 3D structural prototype to visualize the amino acids alterations by UCSF Chimera; For biophysical validation we used project HOPE; Lastly we run conservational analysis by BioEdit and Consurf web server respectively. Our results revealed three novel missense mutations (rs1460413167, rs1295603457 and rs757475450) that are that are more likely to be responsible for disturbance in the function and structure of GPC3. This work provides new insight into the molecular basis of overgrowth Syndrome by evidence from bioinformatics analysis. Three novel missense mutations (rs757475450, rs1295603457 and rs1460413167) are more likely to be responsible for disturbance in the function and structure of GPC3; therefore, they may be assisting as genetic biomarkers for overgrowth syndrome. As well as these SNPs can be used for the larger population-based studies of overgrowth syndrome.

show abstract

“…Some studies show association between GPC3 gene and some types of liver cancer such as hepatocellular carcinoma. [30,34,54,55] Therefore, this study can open the door for novel diagnostic biomarkers for hepatocellular carcinoma. Combination detection of serum GPC3 and pathogenic SNPs through clinical and genetic testing must be positively matched; this can enhance accuracy and efficiency of hepatocellular carcinoma diagnosis.…”

Section: Discussionmentioning

confidence: 91%

Identification of novel key biomarkers in Simpson-Golabi-Behmel Syndrome: Evidence from bioinformatics analysis

Mustafa

Abdelmoneim

Elfadol

et al. 2019

Preprint

View full text Add to dashboard Cite

Background:The Simpson- Golabi-Behmel Syndrome (SGBS) or overgrowth Syndrome is a rare inherited X-linked condition characterized by pre-and postnatal overgrowth. The aim of the present study is to identify functional non-synonymous SNPs of GPC3 gene using various in silico approaches. These SNPs are supposed to have a direct effect on protein stability through conformation changes. Material and methods: The SNPs were retrieved from the Single Nucleotide Polymorphism database (dbSNP) and further used to investigate a damaging effect using SIFT, PolyPhen, PROVEAN, SNAP2, SNPs&GO, PHD-SNP and P-mut, While we used I-mutant and MUPro to study the effect of SNPs on GPC3 protein structure. The 3D structure of human GPC3 protein is not available in the Protein Data Bank, so we used RaptorX to generate a 3D structural model for wild-type GPC3 to visualize the amino acids changes by UCSF Chimera. For biophysical validation we used project HOPE. Lastly we run conservational analysis by BioEdit and Consurf web server respectively. Results: our results revealed three novel missense mutations (rs1460413167, rs1295603457 and rs757475450) that are found to be the most deleterious which effect on the GPC3 structure and function. Conclusion: This present study could provide a novel insight into the molecular basis of overgrowth Syndrome.

show abstract

Can glypican‐3 be a disease‐specific biomarker?

Cited by 21 publications

References 39 publications

Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma

Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma

Identification of Novel Key Biomarkers in Simpson-Golabi-Behmel Syndrome (SGBS): Evidence from Bioinformatics Analysis

Identification of novel key biomarkers in Simpson-Golabi-Behmel Syndrome: Evidence from bioinformatics analysis

Contact Info

Product

Resources

About